Glycogen debranching enzyme (AGL) is a novel regulator of non-small cell lung cancer growth
Metrics: PDF 1051 views | HTML 2129 views | ?
Craig S. Richmond1, Darby Oldenburg1, Garrett Dancik2, David R. Meier1, Benjamin Weinhaus1, Dan Theodorescu3 and Sunny Guin1
1Medical Research, Gundersen Medical Foundation, La Crosse, WI, USA
2Department of Mathematics and Computer Science, Eastern Connecticut State University, Willimantic, CT, USA
3Department of Surgery (Urology), University of Colorado, Aurora, CO, USA
Sunny Guin, email: email@example.com
Keywords: non-small cell lung cancer; hyaluronic acid; AGL; HAS2; RHAMM
Received: September 06, 2017 Accepted: February 28, 2018 Published: March 30, 2018
Glycogen debranching enzyme (AGL) and Glycogen phosphorylase (PYG) are responsible for glycogen breakdown. We have earlier shown that AGL is a regulator of bladder tumor growth. Here we investigate the role of AGL in non-small cell lung cancers (NSCLC). Short hairpin RNA (shRNA) driven knockdown of AGL resulted in increased anchorage independent and xenograft growth of NSCLC cells. We further establish that an increase in hyaluronic acid (HA) synthesis driven by Hyaluronic Acid Synthase 2 (HAS2) is critical for anchorage independent growth of NSCLC cells with AGL loss. Using gene knockdown approach against HAS2 and by using 4-methylumbelliferone (4MU), an inhibitor of HA synthesis, we show that HA synthesis is critical for growth of NSCLC cells that have lost AGL. We further show NSCLC cells without AGL expression are dependent on RHAMM for HA signaling and growth. Analysis of NSCLC patient datasets established that patients with low AGL/high HAS2 or low AGL/high RHAMM mRNA expression have poor overall survival compared to patients with high AGL/low HAS2 or high AGL/low RHAMM expression. We show for the first time that loss of AGL promotes anchorage independent growth of NSCLC cells. We further show that HAS2 driven HA synthesis and signaling via RHAMM is critical in regulating growth of these cancer cells with AGL loss. Further patients presenting with low AGL and HAS2 or RHAMM over expressing tumors might present the ideal cohort who would respond to inhibitors of HA synthesis and signaling.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.